Daclizumab in treatment of multiple sclerosis patients-Reference-Cited by-同舟云学术

Daclizumab in treatment of multiple sclerosis patients

Published:2008-10-09 Issue:2 Volume:15 Page:272-274
ISSN:1352-4585
Container-title:Multiple Sclerosis Journal
language:en
Short-container-title:Mult Scler

Author:

Ali EN¹,Healy BC¹,Stazzone LA¹,Brown BA¹,Weiner HL¹,Khoury SJ¹

Affiliation:

1. Partners MS Center, Brigham and Women’s Hospital, Harvard Medical School, Boston, Massachusetts, USA; Correspondence to: EN Ali, MD, Partners MS Center, Brigham and Women’s Hospital, Harvard Medical School, Boston, Massachusetts, USA.

Abstract

Background Daclizumab is a humanized monoclonal antibody (mAb) that blocks the interleukin-2 receptor alpha subunit (IL-2R-alpha chain; CD25) expressed on activated T cells leading to the inhibition of T-cell expansion, thus strongly reduces brain inflammation in patients with multiple sclerosis (MS). Another mechanism is significant expansion of CD56 (bright) natural killer (NK) cells that in turn inhibit T-cell survival. Objective At the Partners MS center, we have been using Daclizumab in an open-label fashion in patients who fail first line therapy or non-standard immunosuppressive treatment. Our aim was to assess its safety and tolerability in our patient population.

Publisher

SAGE Publications

Subject

Clinical Neurology,Neurology

Link

http://journals.sagepub.com/doi/pdf/10.1177/1352458508097468

Reference8 articles.

1. Case 36-2007

2. Humanized anti-CD25 (daclizumab) inhibits disease activity in multiple sclerosis patients failing to respond to interferon

3. Treatment of multiple sclerosis with an anti-interleukin-2 receptor monoclonal antibody

4. Daclizumab phase II trial in relapsing and remitting multiple sclerosis: MRI and clinical results

5. 5 Kaufman MD Wynn DR Montalban X Wang M Fong A . Preliminary CHOICE results: a phase 2, randomised, double-blind, placebo-controlled multicentre study of subcutaneous Daclizumab in patients with active, relapsing forms of multiple sclerosis on interferon beta. Presented at the 60th American Academy of neurology meeting (AAN); April 12, 2007; Chicago, IL,USA.

Cited by 29 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Novel multiple sclerosis agents-associated cardiotoxicity: A real-world pharmacovigilance study;International Journal of Cardiology;2022-09

2. Novel Multiple Sclerosis Agents-Induced Cardiotoxicity;2021-12-14

3. Spotlight on daclizumab: its potential in the treatment of multiple sclerosis;Degenerative Neurological and Neuromuscular Disease;2016-11

4. Daclizumab;Hospital Pharmacy;2016-11-01

5. Safety of monoclonal antibodies for the treatment of multiple sclerosis;Expert Opinion on Drug Safety;2016-10-31